Suppr超能文献

经皮介入治疗期间活化凝血时间与随后出血并发症之间的关系。

Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications.

作者信息

Hillegass William B, Brott Brigitta C, Chapman Gregory D, Phillips Harry R, Stack Richard S, Tcheng James E, Califf Robert M

机构信息

University of Alabama at Birmingham, Birmingham, Ala 35294-0012, USA.

出版信息

Am Heart J. 2002 Sep;144(3):501-7. doi: 10.1067/mhj.2002.123143.

Abstract

BACKGROUND

Approximately 50% of percutaneous coronary interventions in the United States are performed with unfractionated heparin and no IIb/IIIa agent. The operator must weigh the risks and benefits of more intensive anticoagulation during these percutaneous interventions. This study helps clarify the relationship between patient and procedural factors, such as the intensity of heparin anticoagulation as measured by activated clotting time (ACT), and the risk of blood loss and bleeding complications.

METHODS

Four hundred twenty-nine patients undergoing elective or urgent percutaneous coronary intervention were followed up prospectively for 72 hours after intervention for clinical bleeding complications. Blood loss, defined as the difference between preprocedural and nadir postprocedural hematocrit adjusted for interval transfusions, was also tracked. In-laboratory ACTs, as well as other potential clinical and procedural predictors of blood loss and bleeding risk, were collected and analyzed.

RESULTS

Maximum in-laboratory ACT was significantly related to blood loss as measured by the change in hematocrit (P =.017) and to the risk of major bleeding complications (P =.002). In multivariate analysis, patient age (P =.004), sex (P =.014), procedure length (P <.001), and additional interventions (P <.001) were significant, independent predictors of blood loss. Major bleeding complications were significantly, independently predicted by patient age (P <.001), additional interventions (P =.015), and maximum in-laboratory ACT (P <.001).

CONCLUSIONS

Compared with the other clinical and procedural predictors of bleeding complications, maximum in-laboratory ACT was second only to patient age in significance as a multivariate predictor of postprocedural bleeding complications. Maximum in-laboratory ACT was found to be the most significant modifiable univariate and multivariate predictor of clinical bleeding complications after percutaneous coronary intervention. Particularly in patients with nonmodifiable risk factors for blood loss and bleeding complications such as advanced age, female sex, and multiple and prolonged procedures, avoiding high intensity anticoagulation with unfractionated heparin is associated with lower bleeding risk.

摘要

背景

在美国,约50%的经皮冠状动脉介入治疗使用普通肝素且未使用IIb/IIIa类药物。在这些经皮介入治疗过程中,术者必须权衡强化抗凝的风险与益处。本研究有助于阐明患者及手术相关因素,如通过活化凝血时间(ACT)测量的肝素抗凝强度,与失血及出血并发症风险之间的关系。

方法

对429例行择期或急诊经皮冠状动脉介入治疗的患者在介入治疗后进行72小时的前瞻性随访,观察临床出血并发症。同时记录失血情况,失血定义为术前与术后最低血细胞比容之差,并根据期间输血情况进行调整。收集并分析实验室ACT值以及其他可能的失血和出血风险临床及手术预测因素。

结果

实验室最大ACT值与通过血细胞比容变化测量的失血显著相关(P = 0.017),与大出血并发症风险显著相关(P = 0.002)。在多变量分析中,患者年龄(P = 0.004)、性别(P = 0.014)、手术时长(P < 0.001)及额外干预措施(P < 0.001)是失血的显著独立预测因素。大出血并发症由患者年龄(P < 0.001)、额外干预措施(P = 0.015)及实验室最大ACT值(P < 0.001)显著独立预测。

结论

与其他出血并发症的临床及手术预测因素相比,实验室最大ACT值作为术后出血并发症的多变量预测因素,其显著性仅次于患者年龄。研究发现,实验室最大ACT值是经皮冠状动脉介入治疗后临床出血并发症最显著的可改变单变量及多变量预测因素。特别是对于那些存在失血和出血并发症不可改变风险因素的患者,如高龄、女性以及多次长时间手术患者,避免使用普通肝素进行高强度抗凝可降低出血风险。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验